Van de Veire, S and Stalmans, I and Heindryckx, F and Oura, H and Tijeras-Raballand, A and Schmidt, T and Loges, S and Albrecht, I and Jonckx, B and Vinckier, S and Van Steenkiste, C and Tugues, S and Rolny, C and De Mol, M and Dettori, D and Hainaud, P and Coenegrachts, L and Contreres, JO and Van Bergen, T and Cuervo, H and Xiao, WH and Le Henaff, C and Buysschaert, I and Masouleh, BK and Geerts, A and Schomber, T and Bonnin, P and Lambert, V and Haustraete, J and Zacchigna, S and Rakic, JM and Jimenez, W and Noel, A and Giacca, M and Colle, I and Foidart, JM and Tobelem, G and Morales-Ruiz, M and Vilar, J and Maxwell, P and Vinores, SA and Carmeliet, G and Dewerchin, M and Claesson-Welsh, L and Dupuy, E and Van Vlierberghe, H and Christofori, G and Mazzone, M and Detmar, M and Collen, D and Carmeliet, P (2010) Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease. CELL , 141 (1) 178 - 190. 10.1016/j.cell.2010.02.039.
Full text not available from this repository.
Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.
|Title:||Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease|
|Keywords:||PLACENTA GROWTH-FACTOR, HEPATOCELLULAR-CARCINOMA, PATHOLOGICAL CONDITIONS, MOUSE MODEL, METASTASIS, ANGIOGENESIS, MICE, PROGRESSION, HYPOXIA, LUNG|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Medicine (Division of)|
Archive Staff Only: edit this record